Allevia Study for Tourette's Syndrome

Study Overview

• Study directors: Kevin Shapiro, MD PhD, and Elysa Marco, MD 

• Recruiting: Yes 

• Study Title: A double-blind, placebo-controlled, phase IIb, multi-center, 12-week prospective study to evaluate the efficacy and safety of gemlapodect in adult and adolescent patients with Tourette’s Syndrome 

• Condition: Tourette’s Syndrome 

• Purpose: The purpose of this study is to find out whether gemlapodect, an investigational medication, can reduce tics in individuals with Tourette’s Syndrome. 

Eligibility 

Inclusion criteria: 

• 18 years old and above 

• Diagnosed (or suspected) Tourette’s Syndrome 

• Moderate-to-severe motor and vocal tics 

Exclusion criteria: 

• Uncontrolled seizure disorders 

• Unstable medical or psychiatric illness 

• Conditions such as functional tic-like disorder, Huntington’s chorea, malignant TS, autism, severe anxiety, bipolar disorder, schizophrenia, or Parkinson’s disease 

• Current CBT, CBiT, or neurostimulation 

• Current use of medications for tics – contact our study team to discuss